Reevaluation of Ascorbate in Cancer Treatment: Emerging Evidence, Open Minds and Serendipity

Journal of the American College of Nutrition

Volumn 19, Issue 4, 2000, Pages 423-425

  Padayatty, Sebastian J ^a   Levine, Mark ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Ascorbate; Cancer; Cytotoxicity; Intravenous; Plasma concentration; Vitamin C

Indexed keywords

ASCORBIC ACID; PLACEBO;

ALTERNATIVE MEDICINE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; METASTASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; ANTIOXIDANTS; ASCORBIC ACID; HUMANS; INJECTIONS, INTRAVENOUS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033883604     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2000.10718941     Document Type: Article

References (26)

1. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y: Criteria and recommendations for vitamin C intake. JAMA 281: 1415-1423, 1999.
2. McCormick WJ: Cancer: the preconditioning factor in pathogenesis. Arch Pediat 71: 313-322, 1954.
3. McCormick WJ: Cancer: a collagen disease, secondary to a nutritional deficiency? Arch Pediat 76: 166-171, 1959.
4. Cameron E, Rotman D: Ascorbic acid, cell proliferation, and cancer. Lancet 1: 542, 1972.
5. Cameron E, Pauling L: Ascorbic acid and the glycosaminoglycans. An orthomolecular approach to cancer and other diseases. Oncology 27: 181-192, 1973.
6. Cameron E, Pauling L: The principal trial of vitamin C in Vale of Leven Hospital. In Cameron E, Pauling L (eds): “αCancer and Vitamin C.” Philadelphia: Camino Books, pp 129-145, 1993.
7. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9: 285-315, 1974.
8. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73: 3685-3689, 1976.
9. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75: 4538-4542, 1978.
10. Cameron E, Campbell A: Innovation vs. quality control: an “unpublishable’ clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses 36: 185-189, 1991.
11. Murata A, Morishige F, Yamaguchi H: Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl 23: 103-113, 1982.
12. Campbell A, Jack T, Cameron E: Reticulum cell sarcoma: two complete “spontaneous’ regressions, in response to high-dose ascorbic acid therapy. A report on subsequent progress. Oncology 48: 495-497, 1991.
13. Creagan ET, Moertel CG, Oífallon JR, Schutt AJ, Oíconnell MJ, Rubin J, Frytak S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301: 687-690, 1979.
14. Moertel CG, Fleming TR, Creagan ET, Rubin J, Oíconnell MJ, Ames MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312: 137-141, 1985.
15. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena Jr LR, Wang Y, Levine M: Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 14: 1133-1139, 1997.
16. Pauling L: Diet, nutrition, and cancer. Am J Clin Nutr 30: 661-663, 1977.
17. Cameron E: Vitamin C for cancer. N Engl J Med 302: 299, 1980.
18. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93: 3704-3709, 1996.
19. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypoth 44: 207-213, 1995.
20. Leung PY, Miyashita K, Young M, Tsao CS: Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 13: 475-480, 1993.
21. Benade L, Howard T, Burk D: Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. Oncology 23: 33-43, 1969.
22. Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi-Barre F, Wray W: Vitamin C preferential toxicity for malignant melanoma cells. Nature 284: 629-631, 1980.
23. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH, Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 18: 2487-2493, 1998.
24. Amacher DE, Paillet SC: Ascorbate is detectably mutagenic in the L5178Y TK1/2 cell mutation assay. Cancer Lett 14: 151-158, 1981.
25. Miwa N, Yamazaki H, Ikari Y: Enhancement of ascorbate cytotoxicity by chelation with ferrous ions through prolonged duration of the action. Anticancer Res 6: 1033-1036, 1986.
26. Ernst E: Unconventional cancer therapies: what we need is rigorous research, not closed minds. [Editorial] Chest 117: 307-308, 2000.